By Davit Kirakosyan
Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Oracle, Acelyrin, Ecopetrol, and Ultrapar.
Oracle downgraded again
Oracle (NYSE: ORCL ) was cut to Neutral from Overweight at JPMorgan on Wednesday after the company issued soft Q2 guidance that saw shares drop more than 13% in Tuesday's session.
The company said intense competition within the cloud-computing sector and a reduction in digital spending were weighing on its top-line growth.
JPMorgan also trimmed the software giant's price target to $100 from $112. The analysts said that, while Oracle still has strengths such as strong growth in its cloud segment, AI-related business wins, margin expansion, and healthy recurring revenue growth, its valuation has reached over 25x EV/uFCF, making it difficult to justify a higher price target.
The analysts also cited a recent Generative AI CIO Survey in June that raised questions about Oracle's positioning.
The downgrade follows Tuesday's cut at Monness, Crespi, Hardt, which also downgraded Oracle to Neutral.
Acelyrin slashed at Morgan Stanley following disappointing Izokibep trial results
Shares plunged more than 54% Tuesday after the company’s Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa (HS) didn’t hit the primary endpoint.
The analysts say the downgrade comes on increased uncertainty regarding HS and the challenging short-term prospects for the company. However, Morgan Stanley plans to re-evaluate its views later this year, when they say the setup for the company may be significantly improved.
Two more downgrades
Citi downgraded Ecopetrol (NYSE: EC )to Neutral from Buy with a price target of $12.50.
Goldman Sachs downgraded Ultrapar (NYSE: UGP ) to Neutral from Buy with a price target of $4.00.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.